Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Adam Maass

Endocrinology, Diabetes & Metabolism Springdale, AR Medical Doctor

NPI 1841258738 CMS profile 83928

4301 Greathouse Springs Rd, Ste 100, Springdale, AR 72762

Open in the dashboard

General payments

$502,367

1,065 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Adam Maass of Springdale, AR is reported in the CMS Open Payments database as having received $502,367 across 1,065 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $10,847 38
2021 General $126,779 247
2020 General $152,101 262
2019 General $212,640 518

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adam Maass
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Adam Maass were reported at $0. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Adam Maass Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $212,640 $494 $123–$2,253 $163
2020 $152,101 $335 $85–$1,841 $114
2021 $126,779 $398 $88–$1,981 $132
2022 $10,847 $364 $88–$1,568 $149
2023 $0 $420 $113–$1,614 $160
2024 $0 $440 $121–$1,646 $164
2025 $0 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Lilly USA, LLC $303,770 658 payments
  2. Novo Nordisk Inc $114,946 159 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $25,705 51 payments
  4. Chiasma, Inc. $14,005 16 payments
  5. AbbVie, Inc. $12,972 30 payments
  6. Dexcom, Inc. $12,303 25 payments
  7. Janssen Pharmaceuticals, Inc $5,958 14 payments
  8. Xeris Pharmaceuticals, Inc. $5,414 9 payments
  9. Insulet Corporation $3,475 17 payments
  10. Abbott Laboratories $849 17 payments
  11. Other $2,970 69 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $434,446 444 payments
  2. Travel and Lodging $37,100 228 payments
  3. Consulting Fee $15,664 6 payments
  4. Food and Beverage $11,174 382 payments
  5. Honoraria $3,325 2 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $600 1 payment
  7. Education $58 2 payments
Products named General payments · program years 2019–2022
  1. TRULICITY $209,919 433 payments
  2. JARDIANCE Diabetes $82,194 191 payments
  3. Ozempic $63,643 94 payments
  4. RYBELSUS $28,730 46 payments
  5. JARDIANCE Diabetes $25,705 51 payments
  6. MYCAPSSA $13,958 15 payments
  7. Tresiba $11,734 13 payments
  8. SYNTHROID Immunology $7,217 9 payments
  9. INVOKANA $5,958 14 payments
  10. Synthroid Endocrinology $5,589 11 payments
  11. Other $28,307 182 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

68

Median for Internal Medicine: 777

Drug cost

$26,558

Median for Internal Medicine: $73,373

Branded share of claims

61.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 25 $25,751
Synthroid Levothyroxine Sodium Brand 17 $715
Levothyroxine Sodium Generic 13 $49
Amiloride Hcl Generic 13 $43

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

1,065 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record